Two independent papers reported for the first time the use of GLP1R/GCGR dual agonists as being of enhanced efficacy relative to pure GLP1R agonists in the treatment of rodent obesity, with simultaneous improvement in glycemic control (44, 45). The gene discussed is GLP1R; the disease is obesity disorder.